Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu

Efficacy and Safety of DaxibotulinumtoxinA for Injection to Treat Moderate to Severe Glabellar Lines

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT03014622
Recruitment Status : Completed
First Posted : January 9, 2017
Last Update Posted : October 4, 2019
Sponsor:
Information provided by (Responsible Party):
Revance Therapeutics, Inc.